Turning a corner: Private market posts best month in yearsCore private market metrics suggest positive momentum is brewing and investor sentiment is improving
Turning a corner: Private market posts best month in years
Trading
Data
Solutions
Insights
About
ARS pharmaceuticals is developing an intranasal epinephrine spray for patients at-risk of severe allergic reactions to food, medications and insect bites that could lead to anaphylaxis.
| Date | Funding Round | Funding Raised | Price per Share | Last Known Valuation |
|---|---|---|---|---|
| 8/31/2021 | Series D | $55MM raised | $XXX.XX | $XXX.XX |
| 9/14/2018 | Series C | $20.15MM raised | $XXX.XX | $XXX.XX |
| 4/30/2018 | Series B | $1,000K raised | $XXX.XX | $XXX.XX |
| 4/30/2016 | Series A | $396.84K raised | $XXX.XX | $XXX.XX |
